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RESEARCH
Disruption of the hippocampal 
and hypothalamic blood–brain barrier 
in a diet-induced obese model of type 
II diabetes: prevention and treatment 
by the mitochondrial carbonic anhydrase 
inhibitor, topiramate
Therese S. Salameh1,2 , William G. Mortell1, Aric F. Logsdon1,2, D. Allan Butterfield3 and William A. Banks1,2*
Abstract 
Background: Type II diabetes is a vascular risk factor for cognitive impairment and increased risk of dementia. 
Disruption of the blood–retinal barrier (BRB) and blood–brain barrier (BBB) are hallmarks of subsequent retinal edema 
and central nervous system dysfunction. However, the mechanisms by which diet or metabolic syndrome induces 
dysfunction are not understood. A proposed mechanism is an increase in reactive oxygen species (ROS) and oxidative 
stress. Inhibition of mitochondrial carbonic anhydrase (mCA) decreases ROS and oxidative stress. In this study, topira-
mate, a mCA inhibitor, was examined for its ability to protect the BRB and BBB in diet-induced obese type II diabetic 
mice.
Methods: BBB and BRB permeability were assessed using 14C-sucrose and 99mTc-albumin in CD-1 mice fed a low-
fat (control) or a high-fat diet. Topiramate administration was compared to saline controls in both preventative and 
efficacy arms examining BRB and BBB disruption. Body weight and blood glucose were measured weekly and body 
composition was assessed using EchoMRI. Metabolic activity was measured using a comprehensive laboratory animal 
monitoring system. Brain tissues collected from the mice were assessed for changes in oxidative stress and tight junc-
tion proteins.
Results: High-fat feeding caused increased entry of 14C-sucrose and 99mTc-albumin into the brains of diet-induced 
obese type II diabetic mice. Increased permeability to 14C-sucrose was observed in the hypothalamus and hippocam-
pus, and attenuated by topiramate treatment, while increased permeability to 99mTc-albumin occurred in the whole 
brain and was also attenuated by topiramate. Treatment with topiramate decreased measures of oxidative stress and 
increased expression of the tight junction proteins ZO-1 and claudin-12. In the retina, we observed increased entry of 
99mTc-albumin simultaneously with increased entry into the whole brain during the preventative arm. This occurred 
prior to increased entry to the retina for 14C-sucrose which occurred during the efficacy arm. Treatment with topira-
mate had no effect on the retina.
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Introduction
Type II diabetes mellitus, as well as obesity and consump-
tion of Western diets, are known vascular risk factors for 
cognitive impairment and increased risk of dementia 
[1, 2]. Emerging clinical evidence and studies in animal 
models of metabolic syndrome suggest that alterations in 
the integrity of the cerebrovascular blood–brain barrier 
(BBB) are associated with cognitive decline [3]. This phe-
nomenon also occurs with visual impairment as observed 
with disturbances in blood–retinal barrier (BRB) integ-
rity in diabetic retinopathy. The BBB and BRB provide a 
structural and functional barrier, which impedes and reg-
ulates the influx of compounds from the blood into the 
brain or retina, respectively. There is growing evidence 
suggesting that the disruption of the BRB and BBB is an 
early hallmark of the subsequent retinal edema and cen-
tral nervous system (CNS) dysfunction [4, 5]. However, 
the mechanisms by which diet or metabolic syndrome 
induces dysfunction of the BBB and BRB are not com-
pletely understood.
High-fat (HF) diet consumption causes BBB disruption 
in a variety of animal models of obesity regardless of the 
diet compositions; examples include high energy diets 
and diets rich in saturated fatty acids [3, 6–8]. Type II 
diabetes, designated by hyperglycemia and insulin resist-
ance, is associated with cognitive dysfunction character-
ized by microvascular and neurovascular unit changes. 
Changes in the brain microvasculature are characterized 
by altered permeability, cerebral extravasation of plasma 
molecules, neuroinflammatory and oxidative milieu, and 
progressive loss of neuronal function. These features are 
all associated with type II diabetes, although there are a 
limited number of studies examining the effects of dia-
betes on BBB integrity. In a clinical study, patients with 
type II diabetes showed increased BBB permeability to 
gadolinium diethylenetriamine pentaacetic acid (DTPA; 
570  Da) by magnetic resonance imaging [9]. In an ani-
mal study, in high-fat diet fed insulin-resistant mice, BBB 
dysfunction was shown to precede cognitive decline and 
neurodegeneration [10]. In  KKAy mice, a model of type 
II diabetes, Min et al. demonstrated that blocking angio-
tensin II type 1 receptors to activate peroxisome prolif-
erator-activated receptor (PPAR)-γ protected against 
cognitive decline by preserving the integrity of the BBB 
[11]. More recently, Rom et al. published a paper examin-
ing BBB disruption using the fluorescent tracer, sodium-
fluorescein (NaF) in the leptin receptor deficient db/
db mouse model [12]. These publications assessed BBB 
integrity using either non-quantitative techniques such 
as Evans Blue or IgG extravasation or non-reliable quan-
titative methods such as sodium fluorescein [13]. Here, 
we studied disruption of the BBB and BRB in a diet-
induced obese model of type II diabetes using a quantita-
tive approach of radiolabeled ligands of varying sizes.
Although there is a great deal of diversity in microvas-
cular and macrovascular complications associated with 
type II diabetes, many arise through the same hypergly-
cemia-associated pathways mediated by the overproduc-
tion of superoxide [14, 15]. Increased oxidative stress is 
thought to precede the onset of high-fat diet induced 
insulin resistance and obesity [16]. In numerous studies, 
increased oxidative stress is a major driving force lead-
ing to BBB disruption and cognitive impairment [17–24]. 
Disruption to the brain microvasculature arises in strep-
tozotocin (STZ)-induced rodent models of type I diabetes 
[25, 26]. Inhibition of mitochondrial carbonic anhydrase 
(mCA) has been shown to decrease reactive oxygen spe-
cies (ROS) and oxidative stress in STZ-induced diabetic 
mouse brains [15, 27]. Topiramate  (Topomax®; TPM), a 
mCA inhibitor, prevents BBB disruption in mouse mod-
els of type I diabetes [15, 25]. Also, TPM has been effica-
cious in improving cognitive function in diabetic animal 
models [28].
There are three critical characteristics of brain endothe-
lium that establish the BBB: (i) tight junctions that 
restrict paracellular diffusion of molecules; (ii) a reduc-
tion in the number of endocytic vesicles and lower rates 
of transcytosis relative to peripheral vasculature, and 
(iii) saturable transport of molecules between blood and 
brain. Endothelial cells are connected by specific tight 
junction proteins, such as claudins, occludins and Zona 
occludens (ZO-1, ZO-2, and ZO-3) and exhibit specific 
transport mechanisms and pinocytic vesicles. High-fat 
diet consumption decreases expression of tight junction 
proteins leading to reduced BBB integrity in parts of the 
brain affected by the diet such as the hippocampus, but 
not the parietal cortex or in the whole brain [6, 29–31]. 
In addition, decreased tight junction expression has been 
Conclusions: Blood–brain barrier and blood–retinal barrier dysfunction were examined in a mouse model of 
diet-induced obese type II diabetes. These studies demonstrate that there are spatial and temporal differences in 
14C-sucrose and 99mTc-albumin permeability in the brain and retina of diet-induced obese type II diabetic mice. Topira-
mate, a mitochondrial carbonic anhydrase inhibitor, is efficacious at both preventing and treating BBB disruption in 
this diet-induced obese type II diabetic mouse model.
Keywords: Type II diabetes, Blood–brain barrier, Blood–retinal barrier, Hypothalamus, Hippocampus, Topiramate
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observed in STZ-induced diabetic mice and the leptin-
receptor deficient db/db mice [12, 32].
In this study, we examined the effects of HF-feeding on 
the BBB and BRB of outbred CD-1 mice. Changes in the 
BBB and BRB permeability were quantitatively assessed 
using two different size markers, 99mTc-labeled albumin 
(65  kDa) and 14C-labeled sucrose (342  Da). We demon-
strated that treatment with the mitochondrial carbonic 
anhydrase inhibitor (mCAi), TPM, was able to both pre-
vent disruption from occurring and was efficacious as 
a treatment for BBB disruption in type II diabetes. We 
examined oxidative stress in this model by measuring 
markers of lipid peroxidation and protein oxidation and 
demonstrated that TPM was able to attenuate the oxida-
tive stress induced in this model of type II diabetes mel-
litus. In addition, we examined changes in tight junction 
proteins and demonstrated that TPM treatment was able 
to prevent the loss of claudin-12 and ZO-1 after HF-diet 
consumption.
Materials and methods
Animals
Male CD-1 mice, 8 weeks of age, purchased from Charles 
River Laboratories (Wilmington, MA, USA), were used 
for all experiments. CD-1 mice have not been exten-
sively utilized as a diet-induced obese model. However, 
as these are outbred mice it is important to study diet-
induced obesity in them. In other mouse models, females 
have been found to be resistant to diet-induced obesity 
and less likely to develop hyperglycemia [33, 34], and 
therefore, for these studies we used male mice. Mice had 
ad libitum access to food and water and were placed on a 
12-h light/dark cycle. All studies were performed under 
protocols in adherence with the Guide for the Care and 
Use of Laboratory Animals and approved by the Institu-
tional Animal Care and Use Committee at the Veterans 
Affairs Puget Sound Health Care System (VAPSHCS). 
The data presented here is in compliance with the Ani-
mal Research: Reporting in Vivo Experiments (ARRIVE) 
guidelines.
Study design
Male CD-1 mice (8  weeks of age; n = 235) were split 
into two arms, in the first arm, the prevention arm, mice 
were placed on their respective diets and TPM admin-
istered simultaneously (Fig.  1a). The mice were divided 
into 4 groups: low-fat (LF) diet + saline (n = 40), LF 
diet + TPM (n = 40), high-fat (HF) diet + saline (n = 40), 
HF-diet + TPM (n = 40). As this is an outbred model, 
we assumed that not all mice placed on HF diet would 
develop obesity and become hyperglycemic, thus a high 
n at the start was necessary to achieve statistical sig-
nificance at the endpoint. Mouse diets were purchased 
from Research Diets, Inc. (High fat—D12492; Low fat—
D12450J; New Brunswick, NJ, USA) and matched for 
sucrose (7%). For 16  weeks, topiramate (T0575; Sigma-
Aldrich, St. Louis, MO, USA; TPM) was administered 
daily by subcutaneous injection at a dose of 5 mg/kg. This 
aligns with the dosing for therapeutic use in humans. 
Topiramate was dissolved in dimethylsulfoxide (DMSO) 
at 1:4 (wt/vol) and further dissolved in saline. Control 
mice were given an equivalent amount of DMSO in 
saline. Weekly weight measurement allowed for adjust-
ment in dosing. Non-fasted blood glucose was meas-
ured weekly using the AlphaTRAK2 blood glucometer 
(Zoetis, Parsippany, New Jersey, USA) from the tail vein. 
High-fat fed mice were considered type II diabetic, and 
included in the analysis if their non-fasted blood glucose 
was 2.5 standard deviations above the mean for the LF-
fed control mice. As a result, the permeability studies 
examining the brain and retina had an n in each group 
of: LF diet + saline (n = 10), LF diet + TPM (n = 10), HF 
diet + saline (n = 11), and HF diet + TPM (n = 8). Brain 
tissue and serum were collected for use in oxidative 
stress analysis, protein analysis, immunohistochemical 
analysis, and in the Bioplex Pro Mouse Diabetes assay. 
From this tissue collection, there was an n in each group 
of: LF diet + saline (n = 14), LF diet + TPM (n = 14), HF 
diet + saline (n = 17), and HF diet + TPM (n = 12). After 
adjustment for blood glucose, we had an n in each group 
of: LF diet + saline (n = 14), LF diet + TPM (n = 14), HF 
diet + saline (n = 7), and HF diet + TPM (n = 5).
In the second arm of the study, the efficacy arm 
(Fig. 1a), CD-1 mice were fed LF or HF diet for 20 weeks 
to develop obesity before they were started on TPM. 
There were 75 mice designated for use in this arm of the 
study. During the 20-week feeding period, mice were 
housed four to a cage, and body weight and non-fasted 
blood glucose were monitored monthly. After 20  weeks 
of being fed LF or HF diet, mice were split, two to a 
cage, and into four groups: LF diet + saline (n = 10), LF 
diet + TPM (n = 11), HF diet + saline (n = 27), and HF 
diet + TPM (n = 27). Mice were given an injection of 
saline ± TPM for an additional 16 weeks with weight and 
blood glucose measured weekly, while being maintained 
on their respective diets. After adjustment for blood 
glucose, mice used for permeability analysis totaled: 
LF diet + saline (n = 5), LF diet + TPM (n = 6), HF 
diet + saline (n = 10), and HF diet + TPM (n = 9). Brain 
tissue and serum were also collected from the second 
arm for use in oxidative stress, protein analysis, immu-
nohistochemical analysis, and in the Bioplex Pro Mouse 
Diabetes assay. From this tissue collection, there was an 
n in each group of: LF diet + saline (n = 5), LF diet + TPM 
(n = 5), HF diet + saline (n = 17), and HF diet + TPM 
(n = 18). After adjustment for blood glucose, we had an 
Page 4 of 17Salameh et al. Fluids Barriers CNS            (2019) 16:1 
n in each group of: LF diet + saline (n = 5), LF diet + TPM 
(n = 5), HF diet + saline (n = 15), and HF diet + TPM 
(n = 12).
Three mice died during feeding/treatment (LF 
diet + saline, n = 1, and HF diet + saline, n = 2) due to 
unrelated causes. Sixteen mice died during anesthesia (LF 
diet + saline, n = 1, LF diet + TPM, n = 4, HF diet + saline, 
n = 3, and HF diet + TPM, n = 8).
Radiolabeled albumin and sucrose permeability 
experiments
Mice were anesthetized with an intraperitoneal (ip) injec-
tion of 40% urethane. Once anesthetized, mice received 
an injection into the jugular vein of 0.2 mL of 1% bovine 
serum albumin (BSA) lactated Ringer’s solution contain-
ing 14C-sucrose (10 × 106 cpm/mouse) and 99mTc-albu-
min (5 × 106 cpm/mouse). To reduce exposure to ethanol 
(used by manufacturer to dissolve 14C-sucrose), the etha-
nol was evaporated in the fume hood and the 14C-sucrose 
resuspended in 1% BSA lactated Ringer’s solution. Recov-
ery after evaporation results in 5–6 × 106 cpm/mouse of 
14C-sucrose being injected intravenously. Bovine albu-
min (A7030; Sigma-Aldrich, St. Louis, MO, USA) was 
radioactively labeled with 99mTc using a stannous tartrate 
solution acidified with HCl (20  min room temperature 
incubation) then purified on a Sephadex G-10 column. 
Fractions were collected and assessed using 15% trichlo-
roacetic acid. All proteins showed greater than 90% activ-
ity in the precipitate. The injection circulated for 30 min 
before the vascular space was washed out with ice-cold 
lactated Ringer’s solution (20  mL in 2  min). The brain 
was excised and dissected into: pons-medulla, midbrain, 
cerebellum, frontal cortex, occipital cortex, parietal cor-
tex, thalamus, hypothalamus, hippocampus, and stria-
tum. The retina and vitreous humor were also collected, 
as well as the olfactory bulbs. Serum was collected by 
centrifuging blood (3200  rpm; 10  min at 4  °C) isolated 
from the descending abdominal aorta.
Fig. 1 Effects of diet and topiramate treatment on body composition and blood glucose in CD-1 mice. A schematic diagram illustrating the 
difference in design between arm 1 and 2 of the study (a). Total body weight over the 16 weeks of TPM treatment for arm 1 (b; started with HF 
diet and thus prior to obesity) and arm 2 (f; started after establishment of obesity). HF consumption led to significant increases in body weight 
compared to LF diet in both arms. Topiramate treatment had no effect on weight gain. Change in fat mass as a percentage calculated using fat 
mass measured at the beginning and end of the treatment cycle for arm 1 (c) and arm 2 (g) of the study. Change in lean mass presented as a 
percentage change from the beginning of the treatment cycle for arm 1 (d) and arm 2 (h) of the study. Topiramate had no effect on lean and fat 
mass. Nonfasted measurements of blood glucose over the 16 week treatment period for arm 1 (e) and arm 2 (i). In both arms, HF feeding led to 
a significant increase in nonfasted blood glucose, which was not effected by TPM treatment. Values are expressed as mean ± SD. Significance 
was determined by a one-way analysis of variance followed by Newman–Keuls post-test for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; 
**p < 0.01; #p < 0.001
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99mTc-albumin radioactivity was measured using a 
gamma counter (Wizard2; PerkinElmer, Shelton, CT, 
USA; 3 min counts). The samples were then processed for 
measuring in the beta counter (TriCarb 3110TR; Perki-
nElmer; 60  min counts). Data is expressed as a ratio of 
the amount of radioactivity measured in the tissue and 
serum (T/S) in units of µL/g calculated by the following 
equation:
Body composition
A EchoMRI 4-in-1 instrument (Echo Medical Systems, 
Houston, TX, USA) used quantitative magnetic reso-
nance (QMR) to determine lean body and fat mass of 
the mice at the beginning and end of the study. Triplicate 
measurements were taken using plastic restrainer tubes 
with unanaesthetized mice. The procedure was per-
formed by the Rodent Metabolic and Behavioral Pheno-
typing Core at the VAPSHCS.
Metabolic activity
Metabolic parameters, physical activity, and food intake 
were measured in male CD-1 mice (n = 8 per group) as 
previously described [35]. Animals were monitored for 
72  h (12  h light/dark cycle at thermoneutrality 30  °C) 
in a comprehensive laboratory animal monitoring sys-
tem (CLAMS; Columbus Instruments, Columbus OH, 
USA). Data was collected in 20 min intervals to measure 
oxygen consumption  (VO2), respiratory quotient (RQ), 
energy expenditure, food intake, total physical activity, 
and ambulatory activity. Mice were administered saline 
or 5 mg/kg TPM at 10 a.m. daily.
Bio‑plex pro mouse diabetes assay
A collection of metabolism-related factors [ghrelin, 
glucose-dependent insulinotropic peptide (GIP), gluca-
gon-like peptide-1 (GLP-1), glucagon, insulin, leptin, 
plasminogen activator inhibitor-1 (PAI-1), and resistin] 
were measured in serum samples collected from LF- and 
HF-fed mice treated with saline or 5  mg/kg TPM using 
the murine Bioplex Pro diabetes assay kit according 
to the manufacturers protocol (Bio-Rad Laboratories, 
Hercules, CA, USA). We pooled data from animals in 
arm 1 with arm 2 as there was no significant difference 
between the groups. For example, LF arm 1 was pooled 
with LF arm 2 after t-test was completed to show they 
were not statistically different. After adjusting for blood 
glucose levels, we obtained the following n in each group: 
LF diet + saline (n = 10), LF diet + TPM (n = 11), HF 
diet + saline (n = 8), and HF diet + TPM (n = 8).
T/S (g/µL) =
(
cpm/g brain tissue
)
/(cpm/µL serum)
Oxidative stress measurements
To examine oxidative stress in this model, we measured 
levels of protein carbonyls, 3-nitrotyrosine (3-NT) and 
4-hydroxynonenal (HNE) as previously described [36]. 
Protein carbonyls and 3-NT are measurements of protein 
oxidation and HNE is a measurement of lipid oxidation. 
These measurements were determined immunochemi-
cally. Protein samples (250 ng) from the brains of CD-1 
mice fed LF- and HF-diet with and without TPM treat-
ment were blotted onto a nitrocellulose membrane with 
a slot blot apparatus. In the case of protein carbonyls, 
protein samples were derivatized by 2,4-dinitrophenylhy-
drazine (DNPH) to react with protein carbonyls to form 
protein hydrazones as previously described [29]. The 
membranes were incubated with rabbit polyclonal anti-
DNPH antibody (1:100 dilution) to measure protein car-
bonyls, anti-nitrotyrosine antibody (1:200 dilution) and 
anti-4-hydroxynonenal polyclonal antibody (1:5000 dilu-
tion). Blots were developed using fast tablet (BCIP/NBT; 
Sigma-Aldrich) and quantified using Scion Image (PC 
version of Macintosh- compatible NIH image) software. 
No non-specific background binding of the primary or 
secondary antibodies was found.
Confocal microscopy of tight junction proteins
Dissected mouse brains were immediately post-fixed 
in 4% paraformaldehyde in PBS at 4  °C and then equili-
brated with cryoprotectant (30% sucrose in PBS) and 
stored at 4  °C for up to 6  months until analyzed. Sagit-
tal sections embedded in OCT (Tissue-Tek, Torrance, 
CA, USA) were cut at 50  μm thickness from bisected 
brains with a CM1850UV cryostat (Leica, Buffalo Grove, 
IL, USA). Antigen retrieval was performed by wash-
ing the sections in PBS (3 × 5  min), transferring them 
to 50  mM sodium citrate (pH 9.0) and then heating at 
80  °C for 30  min. Sections cooled to room temperature 
were washed (3 × 5 min) in PBS. A mouse on mouse kit 
(Vector Laboratories, Burlingame, CA, USA) was used in 
accordance with the manufacturer’s recommendations. 
The following antibodies were applied overnight at 4 °C: 
mouse monoclonal anti-occludin (Invitrogen, Carlsbad, 
CA; 1:100), rabbit monoclonal anti-caveolin-1 (D46G3; 
Cell Signaling, Danvers, MA; 1:1000), rat anti-ZO-1 
(Clone R40.76; Millipore Sigma, Burlington, MA; 1:100), 
rabbit anti-GLUT-1 (Millipore Sigma; 1:1000). Goat sec-
ondary antibodies labeled with Alexa Cy3 or Alexa  Fluor® 
488 were applied for 2 h (Jackson Immunoresearch, West 
Grove, PA, USA; 1:1000). Floating tissue sections were 
cover slipped with a drop of  Prolong® Gold Antifade 
Reagent with or without DAPI (Invitrogen, Eugene, OR, 
USA). Confocal microscopy was performed on the hypo-
thalamus with a Leica TCS SP5 II microscope with Leica 
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objectives (20× and 0.7 numerical aperture). All confocal 
microscopic images were acquired and processed using 
image adjustments limited only to linear contrast and 
brightness adjustments applied identically between and 
within groups.
Immunoblot analysis
Whole cell lysate extracts were prepared by lysing hemi-
brains in lysis buffer (25 mM Tris, pH 7.5, 0.15 M NaCl, 
1  mM phenylmethylsulfonylfluoride, 1% Triton X-100 
and complete protease and phosphatase inhibitor cock-
tails, Sigma-Aldrich, Inc.; St. Louis, MO, USA) using 
a beadbeater (2 pulses for 30  s each at 4500  rpm). Cell 
debris was removed by centrifugation at 14,000 rpm for 
20  min at 4  °C. Amount of protein in each sample was 
determined using the BCA protein assay kit (Pierce; 
Rockford, IL, USA). 20 µg of protein lysate was subjected 
to electrophoresis in denaturing 4–12% SDS-PAGE. 
Membranes were probed for caveolin-1 (1:1000; Cell 
Signaling Technology; Beverly, MA, USA), claudin-5 
(1:1000; ThermoFisher Scientific; Waltham, MA, USA), 
claudin-12 (1:1000; ThermoFisher Scientific; Waltham, 
MA, USA) and ZO-1 (1:1000; Invitrogen; Carlsbad, CA, 
USA) overnight at 4  °C. As a loading control, mem-
branes were probed for β-actin (1:10,000). The enhanced 
chemiluminescence western blot was digitalized with 
a LAS4000 CCD imaging system (GE Healthcare, USA) 
and analyzed by ImageQuant TL software.
Statistical analysis
Results are expressed as a mean ± standard deviation. 
Statistical analysis was done on the groups using analy-
sis of variance (ANOVA) followed by Newman–Keuls 
post-test.
Results
Topiramate has no effect on body composition 
and non‑fasted blood glucose levels
Male CD-1 mice (Charles River Laboratories; 8 weeks of 
age) had a baseline weight of 34.21 ± 0.17  g. Mice were 
placed in one of two arms: arm one, examining the role of 
TPM in prevention of BBB dysfunction, started 16-week 
TPM treatment or vehicle simultaneously with the 
change in diet; arm two, examining the efficacy of TPM 
as treatment in reversing BBB disruption, started TPM 
treatment after 20 weeks of diet consumption (when BBB 
disruption is known to be present), continuing mice on 
the assigned diet for an additional 16 weeks.
After 4  weeks of consumption, mice fed a HF-diet 
showed a significant increase in body weight com-
pared to mice on a LF-diet (Fig.  1b). This was main-
tained until the study endpoint. Consistent with the 
literature, TPM treatment had no effect on body weight 
and body composition in these mice (Fig.  1b–d). The 
basal non-fasted blood glucose of the CD-1 mice was 
178.68 ± 2.24  mg/dL. After 9  weeks on HF-diet, CD-1 
mice showed a significant increase in non-fasted blood 
glucose compared to LF-diet fed mice (167.2 ± 10.85 mg/
dL in LF vs. 281.9 ± 20.29  mg/dL in HF; p < 0.0001) 
(Fig. 1e). There was no significant difference in non-fasted 
blood glucose between saline and TPM treated mice on 
either the LF- or HF-diet. CD-1 mice on LF-diet had a 
baseline weight of 49.33 ± 1.31 g, while those on HF-diet 
weighed 67.39 ± 1.19  g (p < 0.0001) after 20  weeks on 
their respective diets. There was no significant difference 
in body weight between saline and TPM treated mice on 
either diet throughout the second arm (Fig.  1f ). There 
was no effect on fat mass (Fig. 1g) or lean mass (Fig. 1h) 
in these animals. In this arm of the study, LF-fed mice 
had a basal non-fasting blood glucose of 150.9 ± 2.6 mg/
dL, while those on the HF-diet had a significantly higher 
basal non-fasting blood glucose of 250.05 ± 9.35  mg/dL 
(p < 0.05). Topiramate treatment had no effect on blood 
glucose levels (Fig. 1i).
Topiramate has no effect on metabolic activity 
and metabolism‑related hormones
Low- and high-fat fed CD-1 mice were placed into met-
abolic chambers after treatment with TPM for 1 week 
or 16 weeks in both arm 1 and arm 2 (Fig. 2). Topira-
mate treatment had no effect on oxygen use (Fig.  2a), 
food intake (Fig.  2c), or activity (Fig.  2e, f ). An RQ of 
0.7 indicates preferential utilization of lipids, whereas 
a value of 1.0 indicates use of carbohydrates. Topira-
mate treatment did not affect the RQ of animals on 
the respective diets (Fig.  2d). In arm 2, HF-diet con-
sumption resulted in a significant increase (p < 0.0001) 
in energy expenditure compared to LF-fed controls 
(Fig.  2b). This increase was significantly attenuated 
with TPM treatment. Analysis of serum metabolites 
showed that HF-feeding led to a significant decrease 
in ghrelin levels (Fig.  3a) and a significant increase in 
GIP (Fig. 3b), insulin (Fig. 3e) and leptin (Fig. 3f ). HF-
feeding caused no significant change in the level of 
GLP-1, glucagon, PAI-1, and resistin compared to the 
LF-treated group. Treatment with TPM had no signif-
icant effect on any of the metabolites measured com-
pared to their LF and HF-treated counterparts (Fig. 3).
High‑fat diet consumption results in BBB permeability 
to 99mTc‑albumin which is attenuated by topiramate 
treatment
Blood–brain barrier dysfunction was measured using 
99mTc-albumin (65 kDa). Results indicate that at 16 weeks 
in arm 1, the whole brain shows increased permeability to 
Page 7 of 17Salameh et al. Fluids Barriers CNS            (2019) 16:1 
Fig. 2 Metabolic activity of topiramate-treated CD-1 mice. Metabolic data collected from the laboratory animal monitoring system (CLAMS) after 
1 week and 16 weeks of TPM administration as a preventative (arm 1) or efficacy (arm 2) agent from LF diet + saline (n = 8), LF diet + TPM (n = 8), HF 
diet + saline (n = 8), and HF diet + TPM (n = 8) in each arm. Mice were administered treatments once daily and measured for 72 h. Data collected 
includes a oxygen consumption  (VO2; mL/h/kg), b energy expenditure (kcal/h), c food intake (FI; grams/h), d respiratory quotient (RQ:  VCO2/
VO2), e total activity (beam breaks/h), and f ambulatory activity (sequential beam breaks/h). Values are expressed as mean ± SD. Significance was 
determined by a one-way analysis of variance followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; 
#p < 0.001
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Fig. 3 Effect of diet and topiramate on metabolism-related hormones. Serum samples collected from LF diet + saline (n = 10), LF diet + TPM 
(n = 11), HF diet + saline (n = 8), and HF diet + TPM (n = 8). Serum was measured for a ghrelin, b glucose-dependent insulinotropic peptide, GIP, c 
glucagon-like peptide-1, GLP-1, d glucagon, e insulin, f leptin, g plasminogen activator inhibitor-1, PAI-1, and h resistin. Ghrelin showed a significant 
decrease after HF-feeding, while GIP, insulin, and leptin showed a significant increase. Topiramate treatment had no significant effect at either 
low- or high-fat feeding. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–
Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01; #p < 0.001
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99mTc-albumin in the HF-fed animals (1.102 ± 0.495 µL/g 
in LF vs. 3.174 ± 2.237  µL/g in HF; p < 0.01) (Fig.  4d; 
Table  1). This observation was made at the whole brain 
level, and specifically in the hypothalamus (Fig.  4e; 
p < 0.05) and cerebellum (p < 0.05), with other regions 
trending towards significance (frontal cortex, parietal 
cortex, occipital cortex, and pons-medulla; p < 0.10). 
Topiramate treatment was able to attenuate BBB dis-
ruption in the whole brain (3.17 ± 0.79  µL/g in HF vs. 
0.667 ± 0.413 µL/g in HF TPM; p < 0.01) (Fig. 4e; Table 1). 
Similar findings were observed in the whole brain after 
Fig. 4 Measurement of blood–brain barrier permeability changes in diet-induced obesity. These histograms are representative of data highlighted 
in Tables 1 and 2. 14C-labeled sucrose (342 Da; Table 2) was used to measure BBB permeability changes in the whole brain (a prevention; g efficacy), 
hypothalamus (b prevention; h efficacy), and hippocampus (c prevention; i efficacy). 99mTc-labeled albumin (65 kDa; Table 1) was used to measure 
BBB permeability changes in the whole brain (d prevention; j efficacy), hypothalamus (e prevention; k efficacy), and hippocampus (f prevention; l 
efficacy). Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test 
for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01; #p < 0.001
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36  weeks of HF-feeding (0.883 ± 0.452  µL/g in LF vs. 
1.672 ± 0.719 µL/g in HF; p < 0.05, Fig. 4j; Table 1). At this 
time point, the hippocampus showed significant increased 
permeability (Fig.  4f; p < 0.05), with other regions trend-
ing towards significance (frontal cortex, parietal cor-
tex, occipital cortex, thalamus, and midbrain; p < 0.10). 
Topiramate treatment also attenuated BBB permeabil-
ity at 36  weeks in arm 2 (1.672 ± 0.719  µL/g in HF vs. 
0.534 ± 0.096 µL/g in HF TPM; p < 0.001, Fig. 4j; Table 1). 
HF-feeding also led to increased permeability to 99mTc-
albumin in the retina at 16 weeks (18.20 ± 7.654 µL/g in 
LF vs. 38.46 ± 20.53  µL/g in HF; p < 0.05) and 36  weeks 
(19.27 ± 7.943  µL/g in LF vs. 36.40 ± 11.65  µL/g in HF; 
p < 0.05, Table 1). Topiramate did not attenuate the effects 
of HF-feeding in the retina and vitreous humor.
High‑fat diet consumption results in hypothalamic 
and hippocampal increased permeability to 14C‑sucrose 
which is attenuated by topiramate treatment
Blood–brain barrier permeability was measured using 
14C-sucrose (342  Da). In Table  2, we show data col-
lected to examine the ability of TPM to prevent BBB 
disruption in the brain. Results indicate that at 16 weeks 
of arm 1 (prevention), the brain shows increased 
permeability to 14C-sucrose in the hypothalamus 
(21.42 ± 6.130  µL/g in LF vs. 50.96 ± 27.71  µL/g in HF; 
p < 0.05; Fig.  4b) and hippocampus (7.753 ± 1.220  µL/g 
in LF vs. 11.73 ± 3.021  µL/g in HF; p < 0.05; Fig.  4c) 
(Table 2). Topiramate treatment was able to attenuate the 
increased permeability to 14C-sucrose in the hypothala-
mus (50.96 ± 27.71  µL/g in HF vs. 23.12 ± 4.293  µL/g 
in HF TPM; p < 0.05, Table  2). Also shown in Table  2 
is data collected to determine the efficacy (arm 2) of 
TPM as a treatment for BBB disruption. Similar to 
our findings in prevention (arm 1), at 36  weeks the 
brain showed increased permeability to 14C-sucrose 
in the hypothalamus (10.51 ± 2.365  µL/g in LF vs. 
16.85 ± 3.627 µL/g in HF; p < 0.05; Fig. 4h) and hippocam-
pus (6.070 ± 1.327  µL/g in LF vs. 8.580 ± 1.862  µL/g 
in HF; p < 0.05; Fig.  4i, Table  2). Topiramate treatment 
was able to attenuate BBB disruption to 14C-sucrose 
in the hippocampus (8.580 ± 1.862  µL/g in HF vs. 
6.594 ± 0.875  µL/g in HF TPM; p < 0.05, Table  2). At 
36  weeks, the retina (138.1 ± 27.51  µL/g in LF vs. 
184.1 ± 25.68  µL/g in HF; p < 0.05, Table  2) also showed 
increased permeability to 14C-sucrose which was not 
attenuated with TPM treatment.
Table 1 Blood–brain barrier and blood–retinal barrier disruption to 99mTc-albumin
99m Tc-albumin was used to assess permeability after TPM treatment
Units, µL/g. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test
LF low-fat diet + saline group, LF TPM low-fat diet + topiramate group, HF high-fat diet + saline group, HF TPM high-fat diet + topiramate group
a Significance in comparison to LF control
b Significance in comparison to HF
Region Prevention Efficacy
LF LF TPM HF HF TPM LF LF TPM HF HF TPM
Whole brain 1.102 ± 0.495 1.599 ± 1.160 3.174 ± 2.237a 0.667 ± 0.413b 0.883 ± 0.452 0.927 ± 0.473 1.672 ± 0.719a 0.534 ± 0.096b
Retina 18.20 ± 7.654 21.37 ± 8.186 38.46 ± 20.53a 29.98 ± 21.77a 19.27 ± 7.943 31.13 ± 8.985 36.40 ± 11.65a 29.62 ± 8.061
Vitreous humor 3.941 ± 1.141 3.591 ± 1.513 6.062 ± 1.613a 6.277 ± 2.636a 5.398 ± 2.516 8.791 ± 4.617 7.917 ± 5.659 6.694 ± 3.447
Olfactory bulb 2.110 ± 1.677 1.701 ± 0.789 2.267 ± 1.871 2.696 ± 1.483 1.697 ± 0.392 1.326 ± 0.653 2.383 ± 1.321 1.486 ± 0.547
Striatum 1.892 ± 0.995 1.746 ± 1.905 1.840 ± 1.167 1.976 ± 1.669 0.795 ± 0.770 0.681 ± 0.512 0.823 ± 0.776 0.412 ± 0.273
Frontal cortex 0.861 ± 0.815 1.081 ± 0.799 2.079 ± 1.736 0.949 ± 0.589 0.752 ± 0.344 0.773 ± 0.356 1.241 ± 0.765 0.522 ± 0.090b
Hypothalamus 1.528 ± 0.411 2.506 ± 2.400 16.41 ± 13.15a 3.123 ± 2.274b 0.815 ± 1.025 0.659 ± 0.667 0.223 ± 0.397 0.579 ± 0.436
Hippocampus 0.630 ± 0.538 2.759 ± 2.324 3.603 ± 3.855 0.984 ± 0.765 0.598 ± 0.458 1.094 ± 0.723 1.742 ± 1.112a 0.339 ± 0.273b
Thalamus 1.196 ± 0.640 1.951 ± 1.424 3.094 ± 3.046 1.273 ± 1.366 0.594 ± 0.510 0.710 ± 0.316 1.328 ± 1.258 0.367 ± 0.219
Parietal cortex 1.119 ± 0.665 1.615 ± 1.486 2.576 ± 2.362 0.871 ± 0.802 0.723 ± 0.412 0.745 ± 0.411 1.359 ± 1.050 0.371 ± 0.125b
Occipital cortex 1.314 ± 0.841 1.982 ± 1.370 2.817 ± 2.521 0.655 ± 0.406 1.070 ± 0.530 0.669 ± 0.547 1.103 ± 0.720 0.406 ± 0.233b
Cerebellum 0.738 ± 0.430 1.087 ± 1.029 2.851 ± 2.483a 0.990 ± 1.150 1.072 ± 0.742 0.899 ± 0.470 0.908 ± 0.458 0.752 ± 0.495
Midbrain 0.947 ± 0.825 1.908 ± 0.943 2.994 ± 2.301 1.936 ± 2.206 0.515 ± 0.288 0.799 ± 0.482 1.260 ± 0.791 0.289 ± 0.220b
Pons-medulla 1.472 ± 0.654 2.191 ± 1.267 3.057 ± 1.969 2.548 ± 1.490 1.361 ± 0.670 1.176 ± 0.420 1.671 ± 0.800 1.598 ± 2.272
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Table 2 Blood–brain barrier and blood–retinal barrier disruption to 14C-sucrose
14 C-sucrose was used to assess permeability after TPM treatment
Units, µL/g. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test
LF low-fat diet + saline group, LF TPM low-fat diet + topiramate group, HF high-fat diet + saline group, HF TPM high-fat diet + topiramate group
a Significance in comparison to LF control
b Significance in comparison to HF
Region Prevention Efficacy
LF LF TPM HF HF TPM LF LF TPM HF HF TPM
Whole brain 9.704 ± 2.586 12.86 ± 2.869 10.67 ± 3.386 11.59 ± 1.884 7.936 ± 3.422 7.568 ± 1.839 9.584 ± 3.593 7.978 ± 2.508
Retina 161.2 ± 38.52 153.4 ± 52.74 161.3 ± 30.87 197.2 ± 42.03 138.1 ± 27.51 166.2 ± 20.10 184.1 ± 25.68a 184.1 ± 31.34a
Vitreous humor 55.53 ± 18.10 51.12 ± 15.29 48.40 ± 13.74 65.70 ± 16.15 40.69 ± 1.939 59.70 ± 17.77 55.29 ± 14.97 60.10 ± 15.10
Olfactory bulb 18.58 ± 6.127 26.77 ± 14.24 23.47 ± 11.87 25.26 ± 13.44 15.74 ± 2.848 17.04 ± 4.781 17.38 ± 4.052 16.57 ± 2.744
Striatum 9.636 ± 2.148 9.643 ± 1.677 11.16 ± 3.700 11.58 ± 2.340 7.375 ± 2.047 6.979 ± 1.390 6.956 ± 1.072 7.978 ± 2.517
Frontal cortex 9.605 ± 3.311 11.22 ± 3.896 9.428 ± 4.862 11.09 ± 2.339 5.973 ± 1.285 6.161 ± 0.789 6.422 ± 1.225 6.029 ± 0.578
Hypothalamus 21.42 ± 6.130 24.46 ± 6.736 50.96 ± 27.71a 23.12 ± 4.293b 10.50 ± 2.365 12.04 ± 2.413 16.85 ± 3.627a 15.51 ± 2.898a
Hippocampus 7.753 ± 1.220 9.704 ± 0.950 11.73 ± 3.021a 12.06 ± 2.466a 6.070 ± 1.327 7.029 ± 1.186 8.580 ± 1.862a 6.594 ± 0.875b
Thalamus 10.05 ± 2.202 10.41 ± 2.625 8.770 ± 3.176 10.54 ± 2.138 7.135 ± 0.815 7.107 ± 1.435 6.421 ± 0.632 6.402 ± 0.674
Parietal cortex 8.412 ± 2.212 10.78 ± 3.310 9.458 ± 3.105 10.79 ± 2.743 6.235 ± 1.416 6.235 ± 1.369 6.413 ± 1.840 5.763 ± 0.827
Occipital cortex 9.764 ± 2.013 12.10 ± 3.037 10.31 ± 2.756 10.53 ± 2.759 7.815 ± 1.858 6.898 ± 1.683 7.451 ± 1.669 7.581 ± 1.401
Cerebellum 8.223 ± 2.127 10.12 ± 2.517 9.427 ± 3.065 10.20 ± 1.709 6.832 ± 1.551 6.890 ± 1.142 8.018 ± 3.389 6.654 ± 1.005
Midbrain 8.889 ± 3.054 13.09 ± 5.116 10.51 ± 3.445 12.87 ± 2.407 7.309 ± 1.458 7.321 ± 1.706 7.913 ± 1.991 6.774 ± 1.046
Pons-medulla 11.95 ± 4.057 13.90 ± 3.024 11.78 ± 4.316 14.71 ± 3.700 9.642 ± 1.321 10.92 ± 2.397 11.92 ± 6.198 10.24 ± 2.984
Fig. 5 Effect of diet and topiramate on oxidative stress. Changes in 4- hydroxynonenal (HNE, a), 3-nitrotyrosine (3-NT, b), and protein carbonyls (c) 
levels in mouse brain homogenates from LF- and HF-fed CD-1 mice treated with or without TPM. HF diet led to a significant increase in HNE and 
3-NT compared to LF controls. These increases were attenuated with TPM treatment. HF diet had no effect on protein carbonyls. The image in d is 
representative of the slot blot data used to collect these values. Values are expressed as arbitrary units, mean ± SD. Significance was determined by 
a one-way analysis of variance followed by Newman–Keuls post-test for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01
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Topiramate treatment decreases oxidative stress levels 
in high‑fat diet fed mice
Oxidative stress was examined in hemibrain samples 
from CD-1 mice fed LF- and HF-diets and treated with 
TPM. Lipid peroxidation, one measure of oxidative stress, 
was assessed by measuring protein-bound 4-hydrox-
ynonenal (HNE), a stable byproduct of lipid peroxidation. 
Elevated levels of protein-bound HNE are indicative of 
oxidative stress. Hyperglycemic HF-fed CD-1 mice had 
significantly increased (p < 0.01) levels of protein-bound 
HNE (Fig. 5a). Topiramate treatment partially prevented 
the increase in oxidative stress caused by HF diet con-
sumption since HF-fed mice treated with TPM were not 
significantly different from the LF controls. Elevated lev-
els of 3-NT, a marker of protein oxidation formed by per-
oxynitrite, which in turn is formed from reaction of nitric 
oxide with superoxide radical anions, is another meas-
urement of oxidative stress. Hyperglycemic HF-fed CD-1 
mice had significantly increased (p < 0.01) levels of 3-NT 
compared to LF controls (Fig. 5b). HF-fed TPM treated 
mice had significantly decreased (p < 0.05) levels of 3-NT 
compared to  their HF-fed controls. There was no sig-
nificant change in protein carbonyls, another measure of 
protein oxidation (Fig. 5c).
Topiramate affects the tight junction proteins, claudin‑12 
and ZO‑1
Immunohistochemical techniques were used to exam-
ine the tight junction proteins ZO-1 and occludin in 
the hypothalamus of CD-1 mice fed LF- or HF- diet 
treated with saline or TPM. HF-fed mice showed a 
significant decrease in ZO-1 (Fig.  6a) and occludin 
(Fig.  6b) fluorescent intensity in the hypothalamus 
(p < 0.05). Topiramate treatment partially prevented the 
decrease in ZO-1 expression caused by HF diet con-
sumption since HF-fed mice treated with TPM were 
not significantly different from the LF controls. Whole 
brain lysate was used to measure protein expression of 
Fig. 6 Effect of diet and topiramate on tight junction protein expression using immunofluorescence. Immunohistochemical techniques were 
used on tissue from the hypothalamus to examine ZO-1 (a) and occludin (b) expression in LF- and HF-fed CD-1 mice treated with or without TPM 
(a). ZO-1 and occludin expression were significantly decreased with HF-diet feeding compared to LF-fed controls. TPM treatment attenuated ZO-1 
expression. GLUT1 was used as a vessel marker for ZO-1 and CAV1 as a vessel marker for occludin. The merged image localizes the tight junction 
staining to the vessels. Scale bar is 50 microns. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance 
followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05
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the tight junction proteins claudin-5, claudin-12, and 
ZO-1, relative to β-actin expression (Fig. 7). HF-diet fed 
mice showed a significant decrease in the tight junc-
tion proteins, claudin-12 (p < 0.05) and ZO-1 (p < 0.05, 
Fig. 7b). Topiramate treatment attenuated the effect of 
HF-diet feeding on the protein expression of claudin-12 
(p < 0.05, Fig. 7b). HF-diet consumption had no signifi-
cant effect on protein expression of claudin-5. In addi-
tion, we measured protein expression of caveolin-1, as 
it is the major structural protein of caveolae, the mem-
brane microdomains involved in various aspects of 
vesicular trafficking [37, 38]. No change in caveolin-1 
expression was observed.
Discussion
Type II diabetes is associated with cognitive dysfunc-
tion resulting in microvascular and neurovascular 
unit changes. Type II diabetes is also associated with 
increased ROS and oxidative stress. Topiramate, a mCAi, 
has been shown to decrease ROS and oxidative stress in 
an STZ-induced mouse model of type I diabetes and to 
reverse cognitive impairment [15, 27, 28]. This approach 
has been effective in preventing BBB disruption in STZ-
induced diabetes by preserving pericyte function [25, 
27, 39, 40]. Here, we examined BBB and BRB disruption 
in a diet-induced obese model of type II diabetes. Two 
paradigms were used; in arm 1 (prevention), mice were 
treated with the mCAi TPM for 16  weeks concurrently 
with the onset of their LF or HF diets; in arm 2 (efficacy), 
the mice were fed their LF or HF diets for 20 weeks and 
then started on the 16 week TPM regimen while continu-
ing their respective diets. As arm 1 examined the effects 
of TPM prior to the onset of BBB disruptions, this had a 
preventative aspect to it, whereas arm 2 examined effects 
of TPM after a time when BBB lesions are established 
and so had an efficacy aspect to it. Therefore, this experi-
mental design was used to determine if TPM is effective 
both in the prevention of BBB disruption and as a poten-
tial treatment.
A potential confounder to this study would have been 
if TPM treatment had resulted in the reversal of diabe-
tes. To examine this, we monitored the effect of TPM on 
body weight as it has been shown, when used in combi-
nation with other drugs, to reduce adiposity in humans 
and rodents and is currently being used as part of an anti-
obesity medication regimen [41–43]. We demonstrated 
that TPM injections had no effect on body weight. This 
was similar to what we observed in studies of STZ-
induced type I diabetes [25]. The mechanism by which 
TPM induces weight loss has yet to be elucidated. Poten-
tial mechanisms include decreasing food intake, reduc-
ing body fat gain, and increasing energy expenditure [42, 
43]. We did not observe changes in body weight which 
could potentially be attributed to the relatively low dose 
of TPM (5 mg/kg vs. 10–100 mg/kg), the route of admin-
istration (subcutaneous injections vs. oral gavage), or that 
TPM was used as a single agent.
Topiramate has the potential to be an insulin sensitiz-
ing agent. This is apparent in rat models [44–46]. There is 
conflicting evidence of this in mouse models and human 
Fig. 7 Effect of diet and topiramate on tight junction protein expression using immunoblot. Whole brain lysate was used to examine expression of 
the tight junction proteins, claudin-5, claudin-12, and ZO-1, and caveolin-1, the major structural protein of caveolae (a). HF-diet consumption led 
to a significant decrease in claudin-12 and ZO-1 expression which was attenuated with TPM treatment for claudin-12 (b). There were no significant 
changes in calveolin-1 or claudin-5. Values are expressed as mean ± SD and relative to the β-actin loading control. Significance was determined by a 
one-way analysis of variance followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; #p < 0.001
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studies [25, 46–49]. Topiramate treatment had no effect 
on non-fasted blood glucose in our model, however, that 
does not imply it did not affect insulin sensitivity. Analy-
sis of the diabetes panel to determine if the TPM treat-
ment had an effect on metabolic hormones revealed that 
HF feeding caused an increase in GIP, leptin, and insulin 
levels and a decrease in ghrelin; consistent with the lit-
erature [50–53]. However, TPM treatment did not alter 
ghrelin, leptin, insulin, GIP, GLP-1, PAI-1, or resistin lev-
els. Thus, the protective effects of TPM are not mediated 
by changes to the metabolic state of the animal. This is 
consistent with TPM protection being facilitated through 
its ability to inhibit mitochondrial carbonic anhydrase 
[15, 25].
Blood–brain barrier permeability was assessed using 
two radiolabeled ligands of varying sizes, 99mTc-albu-
min (65 kDa) and 14C-sucrose (342 Da). The hypothala-
mus and hippocampus showed increased permeability 
to 14C-sucrose with HF-feeding. To date, no studies 
have examined permeability to a ligand this small in 
an in  vivo type II diabetic model using radioactive 
techniques. Assessment was also completed using 
99mTc-albumin (65  kDa). We observed increases in 
99mTc-albumin in the whole brain after 16 weeks of HF-
feeding. Increased permeability to 99mTc-albumin was 
observed in the hypothalamus (at 16  weeks) and hip-
pocampus (at 36  weeks). This was consistent with the 
literature which has used other large ligands, such as 
IgG (150 kDa) to examine BBB disruption [6–8]. Stud-
ies of obese animal models have shown disruption in 
the hypothalamus and hippocampus, similar to our 
findings in type II diabetes, which leads us to conclude 
that hormone levels may potentially drive BBB disrup-
tion more so than hyperglycemia. Transcytosis is a 
transcellular, vesicular based, molecular weight-inde-
pendent form of capillary leakage, whereas paracellular 
transport is the intercellular, tight junction protein-
dependent form of capillary leakage. There is no defini-
tive method in which to distinguish the mechanism by 
which 99mTc-albumin or 14C-sucrose crossed into each 
brain region, since both are capable of entering through 
paracellular and transcytotic routes. However, our 
studies have provided evidence that 99mTc-albumin and 
14C-sucrose cross into the brain of the diabetic mouse 
in distinct patterns from one another, implying that 
they are using different mechanisms of entry that are 
disrupted differentially.
Blood–retinal barrier disruption was also examined 
in this model. Diabetic retinopathy is a major compli-
cation associated with this disease and the major cause 
of blindness in Western countries. Here, we observed 
increased entry of 99mTc-albumin into the retina simul-
taneously with increased entry into the whole brain at 
16  weeks. This occurred prior to increased entry to the 
retina for 14C-sucrose which occurred at 36 weeks. That 
is increased permeability to 14C-sucrose in the retina 
was not found in arm one (16 weeks of HF diet), but was 
found in arm 2 (36 weeks of HF diet). Pericyte loss is a 
major hallmark of diabetic retinopathy, as well as in the 
brain microvasculature, and in other complications of 
type II diabetes [15, 54–57]. Topiramate treatment has 
proven efficacious in preventing pericyte loss in the brain 
of STZ-induced diabetic mice, but not in the retina [15, 
25, 27]. This suggests that the mechanism of disruption 
in the BRB is distinct to that of the BBB. Also, that the 
mechanism of pericyte loss in the two tissue types may 
be independent of one another. The actions of the mCAi 
in lowering ROS may not be the appropriate target to 
preventing pericyte loss in the retina.
High-fat diet consumption is associated with increased 
oxidative stress. Oxidative stress affects BBB integrity 
[17–19]. Studies have shown that brain levels of HNE 
and 3-NT, markers of lipid peroxidation and protein 
oxidation, respectively, are increased in brain tissue, 
and other tissues, including adipose and liver after HF-
diet consumption [58–63]. Protein carbonyls have been 
shown to be increased in the brain with specific types of 
HF-diets which include lard [64] and TPM treatment has 
been shown to reduce these markers of oxidative stress 
in STZ-induced diabetic mice [15, 28]. Topiramate treat-
ment of the hyperglycemic type II diabetic mice in this 
study demonstrated that it was efficacious in reducing 
oxidative stress in this model. Decreasing oxidative stress 
is a mechanism by which TPM acts to improve BBB 
integrity and TPM has been shown to act on pericytes 
to decrease reactive oxygen species and improve cellular 
respiration in the presence of high glucose [39, 40].
In regions of the brain where BBB integrity has been 
disrupted, such as the hippocampus, studies have shown 
that tight junction protein expression is decreased [29, 
30]. However, when regions not affected by HF diet con-
sumption are examined, such as the parietal cortex, or at 
the whole brain level, the effect on tight junction expres-
sion is often absent [6, 31]. In this study, we had access 
to hemibrains of mice shown to have BBB disruption, for 
the preparation of lysate to examine the effect of HF-diet 
consumption and TPM treatment on tight junction pro-
tein expression. We demonstrated that HF-diet led to a 
decreased expression of ZO-1, claudin-12 and occludin, 
which was attenuated or partially attenuated with TPM 
treatment. Examining tight junction protein expression 
in specific regions where BBB disruption has occurred 
may implicate other tight junction proteins in this model. 
This provides a second mechanism by which HF-diet 
consumption leads to a decline in BBB integrity and TPM 
is able to attenuate the effect.
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Obesity has been associated with disorders affecting the 
CNS including depression and cognitive impairment. Cog-
nitive dysfunction has been linked to the consumption of 
a Western diet, a diet that contains both high levels of fat 
(35–60% total kcal) and added sugars. While much of the 
research done on obesity has focused on its effect in the 
hypothalamus, it is now understood that obesity also affects 
other brain regions including the hippocampus [65]. The 
hippocampus, a brain region associated with the control 
of certain learning and memory processes, is particularly 
vulnerable to Western diet consumption. This study has 
demonstrated that the disruption of the hypothalamus and 
hippocampus are evident in animal models of type II diabe-
tes as well as with obesity. The findings of this study demon-
strate that the pattern of BBB disruption in type II diabetes 
is different to that observed in type I diabetes [25]. Type I 
diabetic animal models showed disruption to 14C-sucrose 
(342  Da) in the cortices, thalamus, and midbrain [25, 26], 
while in our diet-induced obese type II diabetic model we 
showed disruption in the hypothalamus and hippocampus. 
This supports findings that cognitive impairment between 
type I and type II diabetics differ from one another [66, 67]. 
Cognitive dysfunction in type I diabetes is characterized by 
a slowing of mental speed and diminished mental flexibility, 
while learning and memory are spared, while in type II dia-
betes, learning and memory are the primary issues of cogni-
tive impairment. Unfortunately, in a recent study, Espeland 
et al. demonstrated that long-term intensive lifestyle inter-
vention, using diet and exercise, in type II diabetics had no 
effect on cognitive function, despite improvements in health 
[68]. This supports our belief that hormone levels play a 
stronger role in determining BBB disruption and subse-
quent cognitive impairment.
Conclusion
Blood–brain barrier and blood–retinal barrier dysfunc-
tion were examined in a mouse model of diet-induced 
obese type II diabetes. Mitochondrial carbonic anhydrase 
inhibition, using the drug topiramate, was used as poten-
tial prevention and treatment strategy in this model. 
Increased permeability to 14C-sucrose was detected in 
the hypothalamus and hippocampus, and increased per-
meability to 99mTc-albumin in the whole brain. In the 
retina, increased entry of 99mTc-albumin was detected 
at 16  weeks while increased entry to 14C-sucrose was 
not detected until 36  weeks. Our studies indicate that 
topiramate is efficacious at both preventing and treat-
ing BBB disruption in the brain, but not retina, in this 
diet-induced obese type II diabetic mouse model. These 
studies demonstrate that there are spatial and temporal 
differences in 14C-sucrose and 99mTc-albumin permeabil-
ity in the brain and retina of diet-induced obese type II 
diabetic mice.
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